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Abstract
Liver disease is associated with qualitative and quanti-
tative changes in the intestinal microbiota. In cirrhotic 
patients the alteration in gut microbiota is characterized 
by an overgrowth of potentially pathogenic bacteria 
(i.e. , gram negative species) and a decrease in autoch-
thonous familiae. Here we summarize the available 
literature on the risk of gut dysbiosis in liver cirrhosis 
and its clinical consequences. We therefore described 
the features of the complex interaction between gut 
microbiota and cirrhotic host, the so called “gut-liver 
axis”, with a particular attention to the acquired risk of 
bacterial translocation, systemic inflammation and the 
relationship with systemic infections in the cirrhotic pa-
tient. Such knowledge might help to develop novel and 
innovative strategies for the prevention and therapy of 
gut dysbiosis and its complication in liver cirrhosis.
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Core tip: In this review we reported the most recent 
concepts on the complex interaction between gut mi-
crobiota and cirrhotic host, namely the gut-liver axis. 
We focused our attention to the clinical consequences 
of gut dysbiosis in cirrhosis such as the acquired risk of 
bacterial translocation, systemic inflammation and the 
relationship with systemic infections.
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INTRODUCTION
The role of  the gut microbiota in liver disease emerged 
in the middle of  the last century with the recognition of  
the relationship between hepatic coma and the absorp-
tion of  nitrogenous metabolites from the intestine[1]. 
This evidence was followed by the description of  a dis-
equilibrium in fecal bacterial composition, with a relative 
abundance of  coliforms in the small intestine of  cirrhot-
ics[2]. A role of  intestinal bacteria in the pathogenesis 
of  hepatic encephalopathy (HE) has been supported by 
clinical studies, demonstrating that intestinal antibiotics 
and non-absorbable disaccharides led to improvement 
of  HE[3]. The increased risk of  gut dysbiosis due to liver 
cirrhosis was already foreseen in the 70’s[4]. Since then 
many new studies have further defined and described the 
alteration of  gut bacteria population in liver cirrhosis and 
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its consequences, mainly due to the passage of  bacteria 
(or bacterial products) towards the liver and systemic 
circulation via the portal circulation or lymphatic system. 
The growing attention in the last years to this issue, the 
so called “gut-liver axis”, is explained by the fact that the 
liver is in fact chronically exposed to gut-derived factors 
including bacteria and bacterial components. The passage 
of  bacteria, or a part of  them, has been recently associ-
ated with systemic inflammation and the complications 
of  cirrhosis, such as hepatic encephalopathy[5] (Figure 1).
This review aims at describing the evolution on the 
understanding of  gut microbiota in end-stage liver dis-
ease over the last decades, the development of  techniques 
to study gut microbiota, the characterization of  gut dys-
biosis and the clinical consequences of  it. 
LITERATURE RESEARCH
Bibliographic searches were performed in MEDLINE 
and EMBASE for the following words (all fields): (‘‘Gut 
Microbiota” or “Bacterial Translocation” or “Inflamma-
tion” or “dysbiosis” or “rifaximin” or “lactulose”) and 
(‘‘cirrhosis” [MeSH]) and (‘‘cirrhosis decompensation” 
[MeSH] or ‘‘hepatic encephalopathy” or “hyperdynamic 
circulation”). Other relevant trials were identified by hand 
searched of  the reference lists of  the clinical trials identi-
fied during the electronic search. A first review was per-
formed on the abstracts of  the articles selected and if  the 
inclusion criteria were satisfied, articles were included in 
the analysis. The information extracted from each of  the 
selected publications included study design details, patient 
and microbiota characteristics, animal models of  dysbio-
sis, methods of  gut bacterial investigation and clinical 
consequences of  dysbiosis. Studies published in abstract 
form only, or in non-English language were excluded.
ARE WE MADE OF BACTERIA?
The human intestinal tract harbors one of  the most 
densely populated ecosystems on earth. The number of  
microorganisms living in the intestine range between 
1014-1015 CFU/mL[6,7]. The gastrointestinal (GI) tract is 
the largest epithelial surface of  the body and is in con-
stant exposure to bacteria. More than 70% of  all micro-
organisms associated with the human body live in the 
intestine, probably related to the richness of  nutrients in 
this area. The total genome of  microorganisms that are 
part of  the flora, called microbiome (60000 genes), ex-
ceeds that encoded by the human genome by a factor of  
approximately 100, providing the expression of  functions 
which have not evolved in humans[8]. We can therefore be 
considered a superorganism consisting of  microbial and 
human cells, and our genome is the sum of  our genes 
and those belonging to the billions of  microorganisms 
that are part of  our microbiota[9]. The distribution of  the 
micro-organisms varies from 10 to 102 bacteria/mL be-
tween stomach and duodenum, to 102 to 108 bacteria/mL 
between jejunum and ileum, culminating in 1012-1013 bac-
teria/mL in the colon[10]. Most bacteria of  faecal origin 
belong to two major phylogenetic lineages: Firmicutes and 
Bacteroidetes. In minor proportion Actinobacteria and Pro-
teobacteria are also present[11]. In healthy subjects, species 
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Figure 1  Association between gut flora, systemic inflammation and the complications of cirrhosis. 
belonging to these phyla live in peaceful coexistence[11]. In 
the last decade, several pathologies have been correlated 
to alterations in the intestinal ecosystem equilibrium - this 
is called dysbiosis. In such a condition there is an increase 
of  potentially pathogenic bacteria species/groups [En-
terobacteriaceae, Escherichia coli (E. coli)], instead of  po-
tentially beneficial bacterial species/groups [Clostridiales, 
Faecalibacterium prausnitzii (F. prausnitzii)]. E. coli is a com-
mensal living in the large intestine; several strains within 
this species, harboring a set of  virulent genes, cause a 
wide range of  diseases[12]. F. prausnitzii is copiously pres-
ent in the human gut, and it is one of  the main produc-
ers of  butyrate, which is the energy source for cells of  
the colonic mucosa. A decrease in Fusobacterium spp. 
in adult patients has been associated with inflammatory 
bowel disease (IBD)[13,14]. Recently the ratio of  F. praus-
nitzii/E. coli expressed as relative abundances, has been 
proposed as a possible indicator of  intestinal dysbiosis in 
adult subjects[15]. 
Gut microbiome in liver disease: Stable component or 
changing companion 
A legitimate question arises when we begin to approach 
the gut microbiota in liver disease; is it the liver disease 
which modifies the gut bacteria or is it the gut dysbiosis 
which causes liver disease? Before answering these ques-
tions we need to discuss the stability of  gut microbiota 
over time. The concept that the individual “fingerprint” 
of  gut microbiota does not change within the host dur-
ing his or her life is now under debate[16]. In their study Li 
et al[16] found a general microbiome signature conserved 
among body habitats of  the same body region and over 
time suggesting that a relatively stable microbial com-
munity structure is maintained throughout the human 
microbiota. Analyses of  the variation for the abundances 
of  phila across the cohort reveal that the detected core 
taxa are also stable. However this observation changed 
when the attention was shifted to oral and stool habitats 
which, in contrast to the rest of  the body, tended to vary 
over time[16].
It is also important to emphasize that a phylum-based 
analysis is not suitable in cirrhosis, especially since Fir-
micutes includes several pathogenic taxa such as Staphy-
lococceae and Enterococcaceae, which indeed are over-
abundant in the sickest population and are very different 
from its other constituents such as Lachnospiraceae and 
Ruminococcaceae in their ultimate impact[17]. 
Indeed recent studies on gut microbiota in cirrhosis 
have shown that microbiota changed when the underly-
ing disease worsened[18]. In advanced liver cirrhosis there 
appears to be an increase in dysbiosis, with a greater 
abundance of  gram-negative taxa (Enterobacteriaceae, 
Bacteroidaceae). The consistent pattern of  microbiota 
change and its association with the severity of  cirrhosis 
cross-sectionally and longitudinally indicates that the 
underlying severity of  cirrhosis may be a stronger deter-
minant of  microbial abundance. The influence of  liver 
disease on gut bacteria composition is also confirmed by 
another study conducted in Asiatic cirrhotic hosts. Chen 
et al[19], by analyzing fecal samples of  36 cirrhotic patients 
and 24 healthy people, found that patients with cirrhosis 
had a reduced concentration of  Bacteroidetes and Lach-
nospiraceae, whereas Proteobacteria, Fusobacterium spp., 
Enterobacteriaceae, Veillonellaceae and Streptococcaceae 
were increased. Interestingly, in their work the authors 
found that the alteration of  microbiota composition cor-
related with the severity of  liver disease. 
But liver disease per se is not the only variable which 
could influence the gut microbiota. In fact, cirrhotics are 
frequently exposed to health care structures and hospital 
admissions, among patients with decompensated cirrho-
sis, are common. The increase of  certain bacterial taxa re-
lated to hospitalization such as Propionibacteriaceae and 
Halomonadaceae have been recently identified as markers 
of  the underlying abnormal intestinal milieu and these 
bacterial taxa have been described as potential pathogens 
in humans[20,21]. The use of  antibiotics during hospitaliza-
tion is also frequent and might interact with the composi-
tion of  gut microbiota. In the study of  Pérez-Cobas et 
al[22], in the first days of  antibiotic treatment the majority 
of  the microbiota included species from the phylum Fir-
micutesa. A drastic shift occurred 4-6 d after the start of  
antibiotic treatment (based on betalactam antibiotics), in 
fact, after one week of  antibiotic therapy the predomi-
nantly active taxa were mainly members of  the Strepto-
coccaceae, Clostridiaceae and Bacteroidaceae (which are 
considered to belong to the “non autochthonous” group 
of  bacteria)[5,18,23]. 
Dietary modifications may also affect the stability 
of  gut microbiota in cirrhotic patients over time. For 
instance, restriction of  dietary protein was considered a 
mainstay in the therapy of  hepatic encephalopathy for 
a long time. More recently, it has been recognized that 
protein energy malnutrition is frequent in advanced liver 
disease and may adversely affect patient outcome[24]. So 
far there are no data on the effect of  diet on gut micro-
biota in liver disease, however an interesting study com-
paring healthy subjects on a “western diet” with those 
on an high fiber diet with low protein and carbohydrate 
content, clearly showed changes in gut microbiota. De 
Filippo et al[25] compared the fecal microbiota of  Euro-
pean children and that of  children from a rural African 
village, where the diet was high in fiber content and low 
in animal derived protein and carbohydrates. The author 
found significant differences in gut microbiota between 
the two groups. The group with a low protein and car-
bohydrate diet showed a significant enrichment in Bac-
teroidetes and a depletion in Firmicutes, with a unique 
abundance of  bacteria from the genus Prevotella and 
Xylanibacter, known to contain a set of  bacterial genes 
for cellulose and xylan hydrolysis, which was completely 
lacking in the subjects on a Western diet. Also, Entero-
bacteriaceae (Shigella and Escherichia) were significantly 
lower in the “Fiber-based diet” as opposed to the “pro-
tein and polysaccharide-rich diet”[25]. 
It is therefore possible that the gut microbiome is a 
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tration of  bile acid, the bacterial population relying on 
7α-dehydroxylation for their energy supply collapses[36]. 
Kakiyama et al[37] showed that dysbiosis in patients 
with cirrhosis is partially due to low bile acid excretion 
into the gut. The total amount of  bile acids in feces 
of  patients with advanced cirrhosis decreased roughly 
5-fold compared to controls and the ratio of  secondary 
vs primary biliary acid decreased significantly. The relative 
scarcity of  secondary biliary acids significantly corre-
lates with the reduction of  the Clostridium cluster XIVa 
group; this is probably due to the high proportion of  
7α-dehydroxylating bacteria within this cluster.
In animal models the production of  secondary bile 
acids by this group of  bacteria cause a positive regulation 
of  bile acid synthesis in the liver. In fact, the higher con-
centration of  secondary bile acids in the ileum implies a 
lower concentration of  tauro-β-muricholic acid, which 
is an inhibitor of  hepatic bile acids synthesis (through 
the inhibition of  FXR signaling)[38]. This interaction un-
veils another part of  the complex interaction between 
gut microbiota and liver function. In this “liver-gut axis 
perspective”, as the severity of  cirrhosis progresses, less 
secondary bile acids reach the large bowel. In particular, 
among the secondary bile acids, deoxycholic acid (DCA) 
is the one which displays the most potent antimicrobial 
activity[39]. Thus, the consequence of  its reduced con-
centration is a higher risk of  bacterial overgrowth in the 
small bowel, often characterized by a reduced F. prausnit-
zii/E. coli ratio[23,40] because of  the relative abundance of  
gram-negative members of  the oral and gut microbiota.
The alteration of  the immune response is another 
relevant player within this context. To date, very little is 
known about the intestinal immune system in patients 
with cirrhosis. It could be possible that in patients with 
cirrhosis a higher stimulation of  Toll Like Receptors 
system occurs due to the higher exposure to pro-inflam-
matory cytokines such as TNF-a, but, despite the state 
of  activation of  mononuclear cells, the innate immune 
response does not seem to be as effective as in controls 
because of  the reduced phagocytic and killing capacity[41].
Liver-gut axis: quantitative changes of gut microbiota in 
cirrhosis
Several studies have demonstrated that patients with cir-
rhosis frequently have a “quantitative” alteration of  gut 
microbiota the so called small intestinal bacterial over-
growth, SIBO[30,42-44]. Therefore, in cirrhosis we have not 
only qualitative differences in microbial communities, 
compared with people without cirrhosis, but also an 
increased intestinal burden of  bacteria. SIBO has been 
documented to correlate with the severity of  liver disease 
and to be a risk factor for clinical decompensation of  liver 
cirrhosis, due to the fact that it favors encephalopathy and 
spontaneous bacterial peritonitis (SBP)[45]. The pathologi-
cal mechanism sustaining the correlation between SIBO 
and decompensation of  cirrhosis is most likely bacterial 
translocation. As the reasons for qualitative dysbiosis are 
multifactorial, also bacterial overgrowth is likely to be mul-
changing companion, which coevolved with the host and 
varies also according to his health and diet. 
Liver-gut axis: Microbiota modification in cirrhosis
In the past, the description of  the qualitative and quan-
titative characteristics of  gut microflora composition in 
cirrhotic patients, has been limited by the scarce reliability 
of  the culture techniques performed on fecal samples or 
on intestinal lumen aspirates. The advent of  molecular 
techniques, mainly based on Polymerase Chain Reaction 
(PCR) of  the bacterial ribosomal 16S rDNA sequence 
are now allowing to perform a complete description of  
the entire bacterial community of  a sample. By means of  
techniques such as Temporal Temperature Gradient Gel 
Electrophoresis (TTGE), Real-time PCR and the recent 
pyrosequencing, it is becoming clear that patients suf-
fering from chronic liver disease could harbor an unbal-
anced gut microbiota composition.
Cirrhotic patients are exposed to a higher risk of  
dysbiosis because of  a variety of  pathological interac-
tions between the liver and the gastrointestinal tract. The 
alteration in intestinal motility, the higher gastric pH and 
the reduced bile acid concentration in the colon seen in 
patients with cirrhosis, may lead to a failure in the control 
of  bacterial intestinal growth[26-28]. The clinical implica-
tions of  this failure in the cirrhotic host might be repre-
sented by the occurrence of  pathological bacterial trans-
location, a higher risk of  intestinal bacterial infections 
and the risk of  decompensation of  liver disease[29].
When the gastric acid barrier fails (drug-induced 
hypochlorhydria, Helicobacter Pylori colonization, autoim-
mune atrophic gastritis, gastric surgery, etc.), “oropha-
ryngeal flora” including mainly Gram-positive bacteria 
(Streptococcus spp., Staphylococcus spp., Micrococcus 
spp., Lactobacillus spp., Neisseria spp., Veillonella spp., 
Stomatococcus spp., Gemella spp., Corynebacterium 
spp., Actinomyces spp., Fusobacterium spp.) increases in 
the stomach, duodenum and proximal jejunum. At the 
same time, when the intestinal clearance is impaired (due 
to a reduction of  small bowel motility), the concentra-
tion of  the “colonic flora” (including Enterobacteriaceae, 
Enterococcus spp., Pseudomonas spp. and Bacteroides 
spp.) increases in the small intestine[30]. The pathogenesis 
of  the decreased intestinal motility in cirrhotic patients 
is not completely clear, but is probably multifactorial: the 
main involved mechanism is the presence of  an auto-
nomic neuropathy[31] which contributes to a delayed oro-
cecal transit time (OCTT)[32]. Moreover, frequent comor-
bidities, such as diabetes, and long term pharmacological 
therapies may also prolong the OCTT. Beta-blockers, by 
improving intestinal motility and by lowering intestinal 
permeability, may reduce the small intestinal bacterial 
overgrowth (SIBO) and decrease the rates of  spontane-
ous bacterial peritonitis[33-35]. In addition, the decrease in 
bile acids entering the intestine appears to favor the over-
growth of  pathogenic and pro-inflammatory members 
of  the microbiome including Porphyromonadaceae and 
Enterobacteriaceae[36], in fact, due to reduced concen-
Giannelli V et al . Dysbiosis and gut-liver axis in cirrhosis
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tifactorial including changes in intestinal motility, absence 
or decreased intestinal levels of  bile acids, and altered 
mucosal innate immunity. Alterations in gastrointestinal 
motility in cirrhosis have been reported and ascribed to 
the effects of  autonomic dysfunction, altered levels of  
neuropeptides and the effects of  inflammatory mediators 
on bowel muscle and nerve[43]. The prevalence of  SIBO, 
assessed by the quantification of  the bacterial density in 
small intestinal aspirate, ranges from 30% to 73%[42,46-48]. 
In contrast, indirect estimates of  SIBO obtained by glu-
cose breath hydrogen test range from 30% to 49% be-
cause of  the limited sensitivity of  this test in the general 
population as well as in cirrhotic patients[48,49].
The methods used to analyze the presence of  SIBO 
are still unsatisfying. In the last decade the diagnostic 
gold standard for SIBO was considered the microbiologi-
cal culture of  jejunal secretions. This test is the oldest 
method used to investigate the small intestinal gut flora. 
However, the invasive nature of  this test and the belief  
that the cultures are often falsely negative because of  the 
difficulties to cultivate obligate anaerobes, or falsely posi-
tive because of  the possible contamination by the oral 
flora, led to the introduction of  indirect, non-invasive 
substitutes. Hydrogen breath tests (HBT) are widely used 
to explore SIBO, however conclusions drawn from vari-
ous studies are controversial: these tests seem to have 
some limitations, which may determine numerous types 
of  bias particularly in cirrhotic patients.
HBTs are based on the fact that in humans the only 
source for hydrogen gas is the bacterial metabolism of  
carbohydrates. For these tests, different carbohydrates are 
orally administered to the patients and the concentration 
of  hydrogen is measured in expired air before and after 
the administration of  the chosen substrate[50]. Glucose 
and lactulose are the most commonly sugar used for di-
agnosis of  SIBO.
The main limitation of  glucose HBT is that the hy-
drogen peak can be due not only to bacterial overgrowth, 
but also to a slow intestinal transit, which can determine 
the presence of  a residue of  complex carbohydrates in 
the colon even after the usual 12 h fasting period; besides, 
an inadequate diet before the test may also influence the 
results (such as a diet rich in fiber). An example of  the 
difficulties to use this test is given by Bauer et al[48] who 
demonstrated that in cirrhotic patients, the glucose HBT 
correlates poorly with the diagnostic gold standard for 
SIBO. 
Lactulose is a carbohydrate which is not absorbed nei-
ther in the small intestine nor in the colon. The limitation 
of  this test is that a rapid transit, which may be due also 
to the effect of  the lactulose itself, is able to blunt a clear 
second peak making it impossible to distinguish SIBO 
from the physiologic colonic fermentation[50].
For these reasons, the sensibility and specificity for 
detecting SIBO of  lactulose HBT are 68% and 44%, and 
for glucose HBT 62% and 83%, compared with jejunal 
cultures[50].
To date, these tests would need to be customized 
for the cirrhotic population and new methods to detect 
the quantitative and qualitative characteristics of  gut mi-
crobiota should be derived by molecular biology (PCR, 
TTGE, Real-time PCR and pyrosequencing).
Other factors to be taken into account: Aetiology of liver 
disease and site of sampling
In studies that have assessed the taxonomic composition 
of  the intestinal microbiota in patients with cirrhosis due 
to different etiologies, the fecal microbial communities 
did not differ depending on the different aetiology of  liv-
er disease[18,51-54]. Therefore, it is conceivable that the con-
dition of  end-stage liver disease itself  may determine the 
content of  the intestinal microbiome. Some differences 
have however been reported by some studies, patients 
with alcoholic cirrhosis had a significantly higher abun-
dance of  Enterobacteriaceae and Halomonadaceae, lower 
abundance of  Lachnospiraceae, Ruminococcaceae, and 
Clostridiales XIV, high endotoxin and lower F. prausnit-
zii/E. coli ratio despite statistically similar model for end-
stage liver disease (MELD) score and BMI compared to 
cirrhotic patients of  non alcoholic etiology. Whereas, in 
patients with cirrhosis due to nonalcoholic steatohepatitis 
(NASH), a higher abundance of  Porphyromonadaceae, 
Bacterioidaceae, and lower Veillonellaceae was found 
compared to their non-NASH counterparts[18]. 
More recently, also the definition of  dysbiosis based 
on qualitative and quantitative DNA analysis of  stool 
specimens is under debate. In fact, studies in non-cirrhot-
ic populations have demonstrated differences between 
the microbiome of  the intestinal mucosa compared with 
the microbiome in the stool[55]. 
In the cirrhotic host one study has reported a sig-
nificant difference in mucosa and stool’s bacteria com-
position[5]. Prominent bacterial genera found at a higher 
abundance in the mucosal microbiome belonged to 
Firmicutes (Blautia, Incertae Sedis XI), Actinobacteria 
(Propionibacterium and Streptomyces), and Proteobac-
teria (Vibrio). Interestingly most bacteria found in higher 
abundance in stool microbiome were Firmicutes (Leuco-
nostoc, Roseburia, Veillonella, and Incertae Sedis XIV). 
Propionibacterium and Vibrio genera were significantly 
more abundant in the mucosa than in the stool. 
In cirrhotic patients taking rifaximin or lactulose 
for HE, the stool microbiome did not show significant 
changes, by converse the mucosal microbiome in the 
rifaximin group showed a significantly decreased abun-
dance of  autochthonous bacteria (Blautia and Roseburia) 
and Veillonellaceae, but an increased abundance of  Pro-
pionibacterium[56].
Route of bacteria: From gut to liver
The term bacterial translocation (BT) was first coined by 
Berg and Garlington in 1979 as the passage of  viable bac-
teria from the gastrointestinal tract through the epithelial 
mucosa into the lamina propria and then to the mesen-
teric lymph nodes (MLN) and possibly other organs[57].
However this definition, along with the advances in 
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DNA and microbiome-associated molecular patterns 
(MAMPs) detecting technology, has been expanded and 
BT is now defined as the migration of  viable microor-
ganisms but also of  microbial products [endotoxins such 
as lipopolysaccharide (LPS), lipoteichoic acid, bacterial 
DNA, peptidoglycans, and fragments, e.g., muramyldipep-
tide, etc.] across an anatomically intact intestinal barrier 
from the intestinal lumen to MLN and other extraintesti-
nal organs and sites[58]. 
The mechanisms implicated in this phenomenon have 
not been completely clarified because of  the difficulties 
in detecting BT in humans. The data on the pathogenesis 
of  BT are derived mainly from animal studies and, to 
date, only few studies have described it in healthy subjects 
and in pathological conditions. 
Bacteria present in the autochthonous flora, in healthy 
people, are able to translocate in low numbers from the 
gut lumen, but are physiologically killed during their pas-
sage through the epithelial barrier or in the MLN, con-
tributing to important immunological functions[59]. These 
events mean that MLN are normally sterile. In cirrhosis, 
alterations of  physiological mechanisms may lead to 
translocation and replication of  the endogenous gut flora 
in MLN[60]. The species that more frequently translocate 
are Enterobacteriaceae, Enterococcus spp and Proteus 
spp. On the other hand, obligate anaerobes are rarely able 
to cross the gastrointestinal barrier[61]. In some cases, the 
translocation of  viable bacteria may induce “spontane-
ous” bacterial infections while the translocation of  bacte-
rial fragments may produce a pro-inflammatory state due 
to the release of  cytokines and nitric oxide. It has been 
suggested that only BT with clinical consequences might 
be defined as “pathological”[29]. The growing attention to 
this phenomenon is motivated by the high impact of  BT 
in terms of  its frequency and its clinical consequences. 
The presence of  enteric-derived bacteria in mesenteric 
lymph nodes and in the venous blood stream occurs 
more frequently in patient with cirrhosis compared with 
controls, and among cirrhotic patients BT is approxi-
mately 5-6 folds more frequent in Child C compared to 
Child A and B. Cirera et al[62], based on the culture of  
mesenteric lymph node in one hundred cirrhotic patients 
undergoing liver transplantation and in thirty-five patients 
without cirrhosis undergoing laparotomy, found that en-
teric-derived bacteria were grown in approximately 8.1% 
Child B and in 31% Child C patients. Mesenteric lymph 
nodes of  controls without cirrhosis were positive for bac-
terial growth in 8% of  cases. Although the methodology 
of  bacterial-culture used by Cirera et al[62] is now replaced 
by PCR technology because of  its higher sensibility in 
detecting BT, their study has the value of  firstly demon-
strating two important issues in liver cirrhosis: (1) the rate 
and degree of  pathological BT depend on the severity of  
liver disease; and (2) the translocation of  entire and viable 
bacteria to MLN is a feature of  decompensated cirrhosis. 
On the contrary, if  we consider the translocation of  non-
vital gut-derived bacteria (such as bacterial DNA or LPS) 
the scenario is rather different. In fact, this latter variant 
of  translocation has been demonstrated to occur also in 
non ascitic mice and the detection of  bacterial DNA in 
the systemic circulation and/or in the mesenteric lymph 
node seems to be independent from the severity of  liver 
disease[63].
Current data suggest two major pathways of  gastro-
intestinal permeability, which might contribute to trans-
location: transcellular, through the enterocytes, under the 
control of  specific enterocyte channels and membrane 
pumps, and paracellular via the tight junctions holding 
epithelial cells together. More commonly, translocation 
generally occurs transcellularly and directly[29]. This route 
is more important than the paracellular route, as it can 
happen also in an intestine with a healthy mucosa. In the 
same way, there are two major routes by which bacterial 
compounds might gain access to the systemic circula-
tion: via the enteric venous system to the portal vein or 
following the enteric lymphatic drainage[59]. Convincing 
evidence suggests that the lymphatic route might be the 
principal pathway of  translocation. Experimental and 
clinical studies detected viable bacteria in MLN. Animal 
studies demonstrated the MLN are the first station where 
translocated bacteria can be found[59,64,65]. The identifica-
tion of  intestinal bacteria in normally sterile MLN is 
considered direct evidence of  BT. As indirect marker, any 
detection of  intestinal bacteria in cultures of  the portal or 
peripheral blood may suggest BT, as well as the detection 
of  endotoxin in peripheral blood. More recent methods 
involving PCR have been introduced for detecting micro-
bial DNA in blood; these methods have a higher sensitiv-
ity than blood cultures for assessing BT[66].
Another limiting aspect of  many studies coming from 
the last decades is represented by the use of  cultures of  
the MLN to investigate this phenomenon: the presence 
of  cultivable microorganisms in the MLN was considered 
proof  of  BT. This assumption implicates an underesti-
mation of  the possibility to translocate for the bacteria 
which are “difficult to culture”, such as the anaerobic 
bacteria. 
Because of  the invasiveness to obtain MLN in hu-
man subjects, these techniques are seldom employed in 
studying BT in humans. Bacteria more frequently present 
in experimental models of  BT, such as Enterobacteria-
ceae, are present in human MLN in only 25% of  cases[62]. 
However, more recent studies applying PCR detection of  
bacterial human DNA found that about 40% of  patients 
with advanced cirrhosis had pathological BT[67]. 
This percentage is similar to that reported previ-
ously[63] and is also similar to the percentage of  cir-
rhotic patients having a positive serum level of  LPS and 
lipopolysaccharide-binding protein[68]. More interestingly, 
the origin of  the detected bacterial DNA is that typical 
of  bacteria that usually are reported to cause episodes of  
infection, such as SBP.
Pathological factors leading to BT in cirrhotic patients 
are SIBO, increased intestinal permeability and alterations 
of  the local host immune system. Bacterial overgrowth 
is probably a prerequisite for the development of  BT; in 
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cirrhotic rats the absence of  SIBO prevents the devel-
opment of  BT and cirrhotic animals without BT had a 
similar count of  cecal aerobic bacteria as healthy rats[44]. 
Indeed, bacteria that translocate to MLN are the same 
ones overgrowing in the intestinal lumen, although not 
all the bacteria present in large quantity are found in 
MLN[44,69,70]. These data suggest that other important fac-
tors are involved in BT. 
The intestinal mucosal barrier has secretory and ana-
tomical means of  preventing the adhesion and penetra-
tion of  microorganisms. Increases in intestinal perme-
ability (IP) in patients with cirrhosis have been reported 
using various methods, and involving the assessment 
of  structural changes, oxidative stress, and alteration in 
enterocyte function[63,71]. If  the epithelium is not physi-
cally damaged, endogenous bacteria translocate by an 
intracellular route through the epithelial lining cells and 
then travel via the lymph to the mesenteric lymph nodes. 
If  the epithelium is physically damaged, bacteria trans-
locate via the intercellular route between the epithelial 
cells to directly access the blood and lymph nodes[59]. The 
increasing interest in intestinal permeability derives from 
the hypothesis that a leaky gut may lead to the passage 
of  toxins, antigens, or bacteria into the body[72], and may 
play a pathogenetic role in the development of  chronic 
liver injury[73]. Some studies have shown an association 
between increased intestinal permeability and severity of  
cirrhosis[72,73]. Nevertheless, an increased IP alone is not 
able to determine pathological BT; in an experimental 
model, Pérez-Paramo et al[65] showed that BT occured 
only in rats with associated SIBO and increased IP, 
whereas it did not occur in rats with either increased IP 
or SIBO.
Both systemic and local immune defenses are im-
paired in cirrhosis[74]. Gut microbiota interact with both 
the innate and the adaptive immune system. Cross talk 
between the mucosal immune system and the endog-
enous microflora favours the mutual growth, survival and 
inflammatory control of  the intestinal ecosystem[75]. 
In cirrhosis, the impairment of  the immune system 
may affect BT in two ways: the impairment of  the local 
immune system (the gut associated lymphoid tissue) in-
creases the ability of  bacteria to translocate to MLN, the 
impairment of  the adaptive immune system affects the 
capability of  these microorganism to replicate and reach 
the systemic circulation, therefore causing the pathologi-
cal consequences of  BT.
In addition, impaired antimicrobial mechanisms may 
further contribute to the development of  bacterial trans-
location in cirrhosis. In a recent study performed on rats, 
Teltschik et al[76] found that bacterial translocation was 
detectable in 40% of  rats with cirrhosis. Compared with 
the group without translocation, these animals exhibited 
diminished intestinal Paneth cell producer antimicrobial 
factors (α-cryptdin 5 and 7 expression). In contrast, ani-
mals with portal vein ligation without cirrhosis had no 
alteration in antimicrobial peptides expression. The de-
crease in Paneth cell antimicrobial protein expression was 
most pronounced in the ileum and the caecum. In keep-
ing with these results, in cirrhotic rats the antimicrobial 
activity toward different commensal strains was reduced, 
especially in the distal ileum and the cecum[76], where 
most of  the bacterial translocation it is thought to occur. 
Clinical consequences of changes in the intestinal 
microbiome 
The growing attention to the role of  the gut microbiome 
in cirrhosis is justified by its key role in bacterial translo-
cation[29], and by the role of  this and other bacterial prod-
ucts such as endotoxin in the pathogenesis of  complica-
tions of  cirrhosis, including hepatic encephalopathy (HE), 
SBP, and other infections[66]. The inflammatory response 
secondary to the higher levels of  circulating bacteria or 
microbiome-associated molecular patterns (MAMP) is 
among the leading causes of  multi-organ failure, acute- 
on-chronic liver failure (ACLF), and death in cirrhosis[77]. 
In Table 1 we summarize the clinical consequences of  
dysbiosis in the cirrhotic host. 
Dysbiosis and infection: In hospitalized cirrhotic pa-
tients with nosocomial SBP, Gram-positive pathogens 
are the main isolated species (70% of  all isolates), with 
methicillin-resistant Staphylococcus aureus in almost 25% 
of  cases[78]. 
In two recent studies performed on cirrhotic patients, 
the authors found an increased abundance of  members 
of  the Enterobacteriacae family[51], which includes impor-
tant Gram-negative pathogens such as Salmonella, Shigella, 
Yersinia, Klebsiella and E. coli. Interestingly, the abovemen-
tioned species, especially E. coli, are those that most fre-
quently cause infections and spontaneous bacteremia in 
patients with cirrhosis[79]. 
There are few data on the role of  dysbiosis as a risk 
factor for the development of  infections. However, a 
significantly preponderance of  gram negative species has 
been found in stool samples from cirrhotic patients with 
SIRS[80]. Within this group a lower ratio of  F. prausnitzii/E. 
coli and higher endotoxin levels have been found com-
pared with cirrhotics without SIRS[80]. Also, in patients 
who developed SIRS and/or died from ACLF, endotoxin 
levels were higher and the microbiota ratio was lower 
with a significantly higher abundance of  gram negative 
species[18,80]. It is conceivable that the reduction in autoch-
thonous taxa can be deleterious for the intestinal mucosa 
given that they produce short-chain fatty acids which 
reduce colonic inflammation and nourish colonocytes, 
compete with pathogenic bacteria for nutrients, produce 
anti-bacterial peptides and may improve the intestinal 
barrier[81]. Therefore, the gut dysbiosis seems to partici-
pate in the disruption of  intestinal epithelial tight junc-
tions and the imbalance of  proliferation and apoptosis 
of  intestinal epithelial cells[81]. The resulting intestinal mu-
cosal atrophy and edema associated with portal hyperten-
sion[82] might explain the higher concentration of  serum 
endotoxin, which has been demonstrated in cirrhotic 
patients with dysbiosis.
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Table 1  Changes in intestinal microbiota and clinical consequence in cirrhosis
Ref. Implicated dysbiosis Potential biological functions
Cirrhosis vs 
healthy people 
Stool 
samples, 
Bajaj et al[5]
Overgrowth of (family): There is a reduction in autochthonous taxa that can be disruptive given that 
they produce short-chain fatty acids that reduce colonic inflammation and 
nourish colonocytes improving the intestinal barrier
   Leuconostocaceae  ↑
   Enterobacteriaceae  ↑↑↑
   Fusobacteriaceae  ↑
   Alcaligenaceae ↑
Reduction of (family):
   Clostridium Incertae sedis XIV ↓↓↓
   Lachnospiraceae  ↓
   Ruminococcaceae ↓
Mucosal 
samples, 
Bajaj et al[5]
Overgrowth of (family - genus): There was a significantly lower abundance of autochthonous genera 
(Clostridium Incertae Sedis XIV) and a higher abundance of potentially 
pathogenic ones (Enterococcus, Proteus, Clostridium) in cirrhotic patients 
compared with the mucosa of healthy controls
   Clostridiaceae - Clostridium ↑
   Enterococcaceae - Enterococcus ↑↑
   Enterobacteriaceae - Proteus ↑
Reduction of (family - genus):
   Clostridium Incertae sedis XIV ↓↓
   Ruminococcaceae - Subdoligranulum  ↓
   Lachnospiraceae  ↓
Cirrhotics with vs 
without infection
Stool 
samples, 
Bajaj et al[18]
Overgrowth of (family): There is an increase in abundance of pathogenic taxa, reduction in 
autochthonous taxa and higher endotoxemia compared to uninfected patients 
despite matching for MELD-score and medication confounders
   Enterobacteriaceae  ↑
Reduction of (family):
   Clostridium Incertae sedis XIV ↓↓
   Lachnospiraceae  ↓↓
   Ruminococcaeae  ↓↓
   Veillonellaceae  ↓
Cirrhotics with 
vs without 
inflammation
Stool 
samples, 
Bajaj et al[18]
Overgrowth of (family): This relative overgrowth of Enterobacteriaceae can result in endotoxemia due 
to increased production with worsening intestinal permeability, which has 
been associated with worsening disease severity and complications in cirrhosis. 
The lower abundance of butyrate producing genera (such as Roseburia and 
Ruminococcaceae) might represent a trophic injury to colonocytes
   Bacteroidaceae
   Enterobacteriaceae
Reduction of (family):
   Clostridium Incertae sedis XIV 
   Lachnospiraceae 
   Ruminococcaeae 
   Roseburia
Cirrhotics with vs 
without hepatic 
encephalopathy
Mucosal 
samples, 
Bajaj et al[23]
Overgrowth of (family - genus): Firmicutes such as members of genera Veillonella, Megasphaera, 
Bifidobacterium, and Enterococcus were higher in HE  whereas Roseburia was 
more abundant in the no-HE group
   Enterococcaceae - Enterococcus  ↑
   Veillonellaceae  - Megasphaera  ↑
   Bifidobacteriaceae - Bifidobacterium ↑↑
   Veillonellaceae  - Veillonella ↑
Reduction of (family - genus):
   Lachnospiraceae  - Roseburia  ↓↓
Higher MELD 
score 
Stool 
samples, 
Bajaj et al[18]
Overgrowth of (family): With the increase in cirrhosis severity, there was a significant increase in 
potentially pathogenic and decrease in autochthonous taxa
   Staphylococcae
   Enterococceae
   Enterobacteriaceae
Reduction of (family):
   Clostridium Incertae sedis XIV 
   Lachnospiraceae 
   Ruminococcaeae 
   Rikenellaceae
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Bacterial translocation and infection in cirrhosis: In 
addition to the potential influence of  BT on the natural 
history of  cirrhosis, another point of  interest is repre-
sented by the higher risk of  developing infections in 
patients once bacteria (or parts of  bacteria) translocate to 
mesenteric lymphnodes and the systemic circulation. Ani-
mal studies demonstrate that the prevalence of  bacterial 
translocation in animals with SBP is twice higher than in 
those without SBP (80% of  BT vs 40%)[83]. Furthermore, 
it has been shown that bacteria isolated from mesenteric 
lymph nodes are genetically identical to those causing 
SBP in the same animal[64]. Even in cirrhotic patients, 
bacteria responsible for post-operative infections, are in 
most cases the same as those recovered from mesenteric 
lymph nodes cultures[84].
Whether the qualitative composition of  the intestinal 
microbiota represent a risk factor for infection in cir-
rhotic patients has not been completely clarified. The 
higher preponderance in cirrhotic stool and intestinal 
mucosa of  those species of  gram negative and positive 
bacteria (Enterobacteriaceae, Streptococcus spp. and Entero-
coccus faecalis)[5,18] that are most widely involved in systemic 
infections, along with the loss of  non pathogenic com-
mensal bacteria, suggest a critical interaction of  intestinal 
dysbiosis and risk of  infection in cirrhosis.
Dysbiosis and inflammation: There is another clini-
cally relevant consequence of  gut bacteria dysbiosis and 
overgrowth which is the induction of  inflammation with 
hemodynamic derangement caused by migration of  intes-
tinal bacteria into the peritoneal cavity and the systemic 
circulation[66].
Inflammatory cytokines contribute to the hyperdy-
namic circulation, portal hypertension[43], impaired liver 
function and impairment of  coagulation[27]. A causal 
relationship between BT-mediated inflammation and 
portal hypertension has been demonstrated in studies 
performed on animal models where the administration 
of  bacterial DNA or LPS leads to exacerbation of  portal 
hypertension[85]. Steib et al[85] infused LPS in the perito-
neum of  rats with bile duct ligation-induced cirrhosis 
and in sham-operate rats and found, after 3 h from infu-
sion, an increased basal portal pressure only in fibrotic 
animals. They also found that, in cirrhotic rats, the LPS 
pretreatment after 3 h further up-regulated the expres-
sion of  the pro-inflammatory pathway driven by TLR4 
system and by MyD88. With this regard, it is interesting 
to report the results of  a recent trial performed on cir-
rhotic patients, which were randomly assigned to receive 
a selective intestinal decontamination with norfloxacin 
(400 mg twice daily) or placebo[86]. In the treated arm, 
the serum endotoxin levels were significantly reduced 
after 4 wk and only in these antibiotic-treated patients 
the authors demonstrated an amelioration of  the hy-
perdynamic circulation compared with controls receiv-
ing placebo. This group of  patients showed a reduced 
cardiac output and a reduced mean HVPG equal to 4 
mmHg, whereas no effects were found on renal function 
(the glomerular filtration rate and the renin-angiotensin 
system did not change significantly after selective intesti-
nal decontamination). These results in cirrhotic patients 
seem to indirectly demonstrate the vicious cycle existing 
between gut-dysbiosis, the pro-inflammatory state driven 
by bacterial translocation and the worsening of  portal 
Cirrhotics with 
vs without  
decompensated 
disease
Stool 
samples, 
Bajaj et al[18]
Overgrowth of (family): With the increase in cirrhosis severity, there was a significant increase in 
potentially pathogenic and decrease in autochthonous taxa
   Enterobacteriaceae  ↑
   Alcaligenaceae ↑
Reduction of (family):
   Clostridium Incertae sedis XIV ↓
   Lachnospiraceae  ↓
   Ruminococcaceae  ↓
   Veillonellaceae  ↓
Aetiology of cirrhosis
   Alcoholic 
   aetiology vs 
   others
Stool 
samples, 
Bajaj et al[18]
Overgrowth of (family): Alcoholic cirrhotics had a significantly higher abundance of Enterobacteriaceae 
and Halomonadaceae, lower Lachnospiraceae, Ruminococcaceae, and 
Clostridialies XIV, despite statistically similar MELD score and BMI compared 
to those without alcoholic etiology
   Enterobacteriaceae  ↑
   Halomonadaeace  ↑
Reduction of (family):
   Clostridiales Incertae sedis XIV  ↓
   Lachnospiraceae ↓
   Ruminococcaceae  ↓
   NASH aetiology 
   vs others
Overgrowth of (family): There is a higher abundance of Porphyromonadaceae, Bacterioidaceae, and 
lower Veillonellaceae in NASH patients than the non-NASH counterparts
   Bacteroidaceae  ↑
   Porphyromonadaceae ↑
Reduction of (family):
   Veillonellaceae  ↓
Normalized relative abundance: ↑/↓: 1-2 fold of increase/reduction vs control; ↑ ↑/↓ ↓: 3-6 fold of increase/reduction vs control; ↑ ↑ ↑/ ↓ ↓ ↓ > 7 fold of 
increasereduction vs control. NASH: Nonalcoholic steatohepatitis; MELD score: Model for end-stage liver disease score; BMI: Body mass index. 
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hypertension. The ability of  norfloxacin to selectively 
alter the microbiota of  the intestine could be responsible 
for the hemodynamic changes seen in these patients. 
Norfloxacin is incompletely absorbed from the intestine, 
is mostly active against aerobic gram-negative bacteria 
and rarely causes bacterial resistance.
In another recent study, the investigation was focused 
on the non-absorbable antibiotic rifaximin, and the au-
thors found similar results to norfloxacin. In fact, treated 
mice with rifaximin had a reduction of  portal pressure 
and fibrosis in vivo compared to the untreated group. 
This agent is concentrated in the gastrointestinal tract, 
thereby modulates the gram negative flora and reduces 
the production of  intestinal bacteria-derived LPS with 
no systemic toxicity or resistance. In their elegant study, 
Zhu et al[87] went further in their analysis of  mechanism 
of  rifaximin on portal hypertension and inflammatory 
amelioration. 
Since TLR4 is the canonical receptor for LPS, they 
used TLR4 mutant mice which were therefore unable to 
activate the TLR4 pathway in response to LPS presenta-
tion. In these TLR4 mutant animals, the exposure to LPS 
was not reflected by any change in portal hypertension, 
angiogenesis, fibrosis, and pro-inflammatory state even 
without rifaximin[87]. The TLR4 mutant mice showed 
comparable and, in some cases, less portal hypertension 
and inflammation than wild type cirrhotic mice who 
received rifaximin. Together, these data suggest that the 
beneficial effect of  rifaximin on liver inflammatory state 
and portal hypertension are also mediated by the down 
regulation of  the LPS-TLR4 pathway as a result of  the 
reduced gram negative flora. 
Rifaximin is of  topical interest since it is FDA ap-
proved for treatment of  hepatic encephalopathy, with 
an acceptable safety profile in patients with chronic liver 
disease. Therefore, the modulation of  the microbiota 
might represent a potential therapeutic strategy in the 
management of  liver disease. Intestinal decontamination 
with nonabsorbable antibiotics (i.e., rifaximin) is also an 
effective treatment for minimal and overt hepatic en-
cephalopathy[88,89]. 
In this scenario, recent studies have utilized a simple 
ratio of  ‘‘good vs bad’’(Firmicutes/bacteroides) taxa 
abundance (termed the cirrhosis dysbiosis ratio) to identi-
fy patients at higher risk of  cirrhosis complications. This 
ratio is based on prior studies in patients with cirrhosis, 
which includes the highly relevant taxon Enterobacteria-
ceae, which is important in complications of  cirrhosis, 
and produces one of  the most potent endotoxins[18]. 
Interestingly, Bajaj et al[18] found that patients with 
cirrhosis developed clinical decompensation (such as 
hepatic encephalopathy) more frequently in the presence 
of  a relatively reduced abundance of  taxa considered 
benign and autochthonous, including Lachnospiraceae, 
Ruminococcaceae, and Clostridiales, Incertae Sedis XIV 
(from now on called Clostridiales, XIV) and a relatively 
higher abundance of  others, particularly Enterobacte-
riaceae and Bacteroidaceae[18,23]. Moreover they demon-
strated again how the severity of  liver disease per se nega-
tively affects the composition of  the microbiota; in fact 
the MELD score seemed to negatively correlated with 
“positive” bacteria such as Clostridiales XIV, Lachno-
spiraceae and Ruminococcaceae and with Rikenellaceae, 
and positively with potentially pathogenic taxa such as 
Staphylococcaceae, Enterococcaceae and Enterobacte-
riaceae. It is interesting to note that the “quality” of  gut 
microbiota reflected the “quantity” of  serum levels of  
endotoxin. In fact, in patients with lower concentration 
of  faecal Clostridiales XIV, Lachnospiraceae and Rumi-
nococcaceae, the levels of  endotoxin were significantly 
higher. Among other species of  interest, they also found 
a reduction in Veillonellaceae and Porphyromonadaceae 
with worsening liver disease compared to healthy con-
trols. Considering the ratio between autochthonous and 
pathogenic bacteria (Firmicutes/bacteroides), this was 
about three times higher in controls compared to all cir-
rhotic patients.
The liver is the first extraintestinal organ encountered 
by the venous blood from the small and large intestines 
draining from the portal vein. For this reason, the liver is 
vulnerable to the exposure of  bacterial products translo-
cated from the gut lumen via the portal vein. In a healthy 
organism only minor quantities of  translocated bacterial 
products reach the liver. In general, the hepatic immune 
system tolerates these bacterial products avoiding an 
uncontrolled immune responses, a phenomenon known 
as “liver tolerance”[90]. The first immunological response 
to the presence of  bacteria (or MAMPs) is driven by the 
activation of  innate immune system. In particular, trans-
located bacterial products augment the activation of  he-
patic immune cells through pattern recognition receptors 
including Toll-like receptors (TLRs). The activated TLR 
system induces the production of  cytokine such as IL-1 
and IL-6 and type I IFN. In recent studies, this kind of  
inflammation without infection has been defined as sterile 
inflammation and is caused by the release from damaged 
cells or tissues of  some factors, such as alarmin, which 
trigger TLR signaling[91]. TLR system is a complex system 
which involves more than 10 members of  the TLR fam-
ily but the description of  this intricate response is outside 
the scope of  this review[92,93]. It is however of  interest to 
mention the role of  TLR4 (which binds lipopolysaccha-
ride) because its single nucleotide polymorphism (SNP) 
seems to correlate to the risk of  liver cirrhosis in patients 
with chronic hepatitis C infection[94].
In two different study performed on animal models 
using mice knockout for TLR4 co-receptors (i.e., CD14 
and LPS-binding protein), the authors found a lower 
induction of  liver fibrosis mediated by bile duct liga-
tion[95,96]. Their results showed that TLR4-mutant mice 
have similar levels of  elevated LPS in the blood com-
pared to wild-type mice but a lower liver fibrosis[97]. In ad-
dition, in another study mice deficient of  the TLR4, LPS 
binding protein and CD14 were shown to be resistant to 
alcohol-induced liver damage[97,98]. Finally, gut sterilization 
with antibiotics decreased plasma LPS levels and liver 
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steatosis, inflammation and injury after chronic ethanol 
exposure[99].
The potential therapeutic options are fascinating 
because they might allow the possibility to interrupt the 
vicious cycle existing between gut dysbiosis and liver 
disease. To date, relative small randomized controlled 
trials have been addressed to evaluate the effects of  gut 
flora manipulation in patient with cirrhosis. In Table 2 
we summarize the most relevant studies, with greater at-
tention to those aimed at verifying the clinical benefits of  
gut microflora modification. Overall, they agree with the 
result that targeting the gut microbiota might be effective 
in reducing the proliferation of  harmful gut flora and 
consequently it limited the complications of  dysbiosis 
such as the pathological bacterial translocation.
In these previous studies, the “manipulation” of  gut 
bacteria has been done by prebiotics (i.e., dietary ma-
nipulation/supplementation), probiotics and systemic or 
poorly absorbable antibiotics. We do not consider faecal 
transplant in our review because there are no data in cir-
rhotic patients, so far. On the whole, these studies dem-
onstrated the positive effect of  microbiota modulation 
Table 2  Effects of the intervention on gut microbiota composition and its clinical and/or biochemical consequences 
Ref. Type of 
study
Category of patients Therapy Clinical outcome Microbiota changing
Albillos et al[68] RCT 102 Cirrhotics/
30 controls 
Norfloxacin 400
mg orally TD vs Placebo
Norfloxacin
improved cardiac index in 
patients with elevated LBP, no 
improvement in portal pressure 
in the rest of patients
NA
Bass et al[100] RCT 299 cirrhotics Rifaximin 550 mg twice 
daily (140 patients) vs placebo 
(159 patients) 
Rifaximin group maintained 
remission from hepatic
encephalopathy more effectively 
than did placebo
NA
Rayes et al[104] RCT 66 cirrhotics 
underwent LT
Pediacoccus
pentosaceus + Leuconostoc 
mesenteroides + Lactobacillus 
paracasei 
and L. plantarum vs Placebo
Significant reduction of 
post-operative bacterial 
infections
(3% vs 48% of controlls) 
NA
Lata et al[105] RCT 39 cirrhotics Cirrhotics were randomly 
allocated to treatment with E. coli 
Nissle or placebo for 42 d
In probiotic group , the authors 
found a trend of significant 
lowering of the endotoxemia 
(P = 0.07) and improvement of 
Child-Pugh score (P = 0.06)
Restoration of normal colonic 
colonization in pts treated 
with E. coli Nissle
Gupta et al[106] RCT 94 cirrhotic 
patients with large 
oesophageal varices
without history of 
variceal bleeding 
Patients were randomized to three 
treatment
Groups: (1) propranolol plus 
placebo 
(2) propranolol
Plus norfloxacin 400 mg BD
(3) propranolol plus
VSL#3, 900 billion/d
Group 2 and 3 showed a greater 
reduction in HVPG than 
Group 1. In addition, in Group 2 
and 3 the
TNF-a levels were significantly 
lower than Group 1
NA
Bajaj et al[107] RCT 25 nonalcoholic 
MHE cirrhotics 
(defined by 
a standard 
psychometric 
battery) 
Cirrhotics were randomized to
Receive yogurt contained 
Lactobacillus bulgaricus and 
Streptococcus
Thermophilus or no treatment for 
60 d in a 2:1 ratio
Twelve of 17 yogurt patients 
reversed MHE
(71% on intention-to-treat and 
86% on per-protocol analysis)
compared to 0% in the 
no-treatment group (P = 0.0030)
Levels of citokyne were similar 
between groups 
NA
Bajaj et al[56] PS 20 nonalcoholic 
MHE cirrhotics 
(defined by a 
standard 
psychometric 
battery)
Patients received rifaximin 550 mg 
BID for 8 wk and the 
psychometric tests, stool analysis 
and blood test were repeated at 
the end of the study
There was a significant 
improvement in cognition test 
performance and a reduction of 
endotoxemia
after rifaximin
After rifaximin there was a 
significant reduction in the 
abundance of faecal 
Veillonellaceae
(P = 0.025) and increase in the 
abundance of Eubacteriaceae
(P = 0.042) 
Bergheim et al[101] Animal 
model
Mice with induced 
NAFLD
For 8 wk, C57BL/ J6 mice had free 
access to solutions containing 30% 
glucose, fructose, sucrose, or water 
sweetened with artificial 
sweetener  or plain water
The group treated with 
polymixin B and Neomycin were 
protected against the 
fructose-induced NAFLD and 
had a lower level of endotoxin
NA
RCT: Randomized controlled study; PS: Pilot study; LT: Liver translanted; NA: Not applicable (the study did not provide microbiota characterization); BD: 
Bis in die; HVPG: Hepatic venus pressure gradient; NAFLD: Non-alcoholic fatty liver disease.
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in term of  reduction of: fibrogenesis, endotoxin plasma 
concentration, portal hypertension and pro inflamma-
tory state[56,68,100,101]. There is however still a lack of  data 
regarding the effect of  these interventions on the spe-
cific gut bacteria composition in liver cirrhosis, with the 
exception of  the recent studies conducted by Patidar et 
al[102], which accurately studied the composition of  micro-
biota after lactulose and/or rifaximin therapies. To date, 
the strongest evidence regarding the clinical benefit of  
gut modulation in cirrhosis is still based on the large liter-
ature on hepatic encephalopathy treatment, and rifaximin 
plus lactulose resulted to be superior to placebo in treat-
ing the overt and minimal hepatic encephalopathy. With 
this regard we refer the reader to the already published 
studies which extensively described this clinically relevant 
aspect of  gut-liver axis[102,103]. 
CONCLUSION
We have reviewed the large literature supporting the 
concept of  the strict interplay between gut bacteria and 
liver disease. Gut microbiota alteration appears to be 
rather common in advanced liver disease and it sustains 
the concept of  how gut microbiota phenotype and the 
presence of  pathological bacterial translocation are de-
terminant factors for liver function and hepatic chronic 
inflammation. Herein, we also described the relevance of  
the clinical consequences of  microbiota alteration. The 
clinical implications of  dysbiosis is that future therapeutic 
approaches to liver cirrhosis, especially in decompensated 
patients, should consider the gut-liver axis.
REFERENCES
1 Phillips GB, Schwartz R, Gabuzda GJ, Davidson CS. The 
syndrome of impending hepatic coma in patients with cir-
rhosis of the liver given certain nitrogenous substances. N 
Engl J Med 1952; 247: 239-246 [PMID: 14947933 DOI: 10.1056/
NEJM195208142470703]
2 Martini GA, Phear EA, Ruebner B, Sherlock S. The bacterial 
content of the small intestine in normal and cirrhotic sub-
jects: relation to methionine toxicity. Clin Sci (Lond) 1957; 16: 
35-51 [PMID: 13414138]
3 Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, 
Merli M, Romiti A, Candiani C, Capocaccia L. Effect of lacti-
tol and lactulose administration on the fecal flora in cirrhotic 
patients. J Clin Gastroenterol 1990; 12: 433-436 [PMID: 2398251 
DOI: 10.1097/00004836-199008000-00016]
4 Thomas HC, McSween RN, White RG. Role of the liver in 
controlling the immunogenicity of commensal bacteria in the 
gut. Lancet 1973; 1: 1288-1291 [PMID: 4126078 DOI: 10.1016/
S0140-6736(73)91300-7]
5 Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, 
White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet 
PM. Colonic mucosal microbiome differs from stool micro-
biome in cirrhosis and hepatic encephalopathy and is linked 
to cognition and inflammation. Am J Physiol Gastrointest Liver 
Physiol 2012; 303: G675-G685 [PMID: 22821944 DOI: 10.1152/
ajpgi.00152.2012]
6 Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbio-
ta in health and disease. Physiol Rev 2010; 90: 859-904 [PMID: 
20664075 DOI: 10.1152/physrev.00045.2009]
7 Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic 
approaches for defining the pathogenesis of inflammatory 
bowel diseases. Cell Host Microbe 2008; 3: 417-427 [PMID: 
18541218 DOI: 10.1016/j.chom.2008.05.001]
8 Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon 
JI. Host-bacterial mutualism in the human intestine. Science 
2005; 307: 1915-1920 [PMID: 15790844 DOI: 10.1126/sci-
ence.1104816]
9 Burcelin R, Serino M, Chabo C, Garidou L, Pomié C, Court-
ney M, Amar J, Bouloumié A. Metagenome and metabolism: 
the tissue microbiota hypothesis. Diabetes Obes Metab 2013; 
15 Suppl 3: 61-70 [PMID: 24003922 DOI: 10.1111/dom.12157]
10 Sartor RB. Microbial influences in inflammatory bowel dis-
eases. Gastroenterology 2008; 134: 577-594 [PMID: 18242222 
DOI: 10.1053/j.gastro.2007.11.059]
11 Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, 
Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan 
M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, 
Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc 
M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons 
N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, 
Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, 
de Vos WM, Brunak S, Doré J, Antolín M, Artiguenave F, 
Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, 
Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner 
KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber 
W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, 
Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo 
Minardi R, M’rini C, Muller J, Oozeer R, Parkhill J, Renault 
P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner 
K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, 
Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human 
gut microbiome. Nature 2011; 473: 174-180 [PMID: 21508958 
DOI: 10.1038/nature09944]
12 Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia 
coli. Nat Rev Microbiol 2004; 2: 123-140 [PMID: 15040260 DOI: 
10.1038/nrmicro818]
13 Sokol H, Lay C, Seksik P, Tannock GW. Analysis of bacterial 
bowel communities of IBD patients: what has it revealed? 
Inflamm Bowel Dis 2008; 14: 858-867 [PMID: 18275077 DOI: 
10.1002/ibd.20392]
14 Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, 
Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, 
Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. 
Imbalance in intestinal microflora constitution could be in-
volved in the pathogenesis of inflammatory bowel disease. 
Int J Med Microbiol 2008; 298: 463-472 [PMID: 17897884 DOI: 
10.1016/j.ijmm.2007.07.016]
15 Schippa S, Iebba V, Santangelo F, Gagliardi A, De Biase RV, 
Stamato A, Bertasi S, Lucarelli M, Conte MP, Quattrucci S. 
Cystic fibrosis transmembrane conductance regulator (CFTR) 
allelic variants relate to shifts in faecal microbiota of cystic 
fibrosis patients. PLoS One 2013; 8: e61176 [PMID: 23613805 
DOI: 10.1371/journal.pone.0061176]
16 Li K, Bihan M, Methé BA. Analyses of the stability and core 
taxonomic memberships of the human microbiome. PLoS 
One 2013; 8: e63139 [PMID: 23671663 DOI: 10.1371/journal.
pone.0063139]
17 Goel A, Gupta M, Aggarwal R. Gut microbiota and liver 
disease. J Gastroenterol Hepatol 2014; 29: 1139-1148 [PMID: 
24547986 DOI: 10.1111/jgh.12556]
18 Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White 
MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, 
Sikaroodi M, Gillevet PM. Altered profile of human gut mi-
crobiome is associated with cirrhosis and its complications. 
J Hepatol 2014; 60: 940-947 [PMID: 24374295 DOI: 10.1016/
j.jhep.2013.12.019]
19 Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, 
Giannelli V et al . Dysbiosis and gut-liver axis in cirrhosis
16807 December 7, 2014|Volume 20|Issue 45|WJG|www.wjgnet.com
Zhu B, Li L. Characterization of fecal microbial communities 
in patients with liver cirrhosis. Hepatology 2011; 54: 562-572 
[PMID: 21574172 DOI: 10.1002/hep.24423]
20 Park HJ, Na S, Park SY, Moon SM, Cho OH, Park KH, 
Chong YP, Kim SH, Lee SO, Kim YS, Woo JH, Kim MN, 
Choi SH. Clinical significance of Propionibacterium acnes re-
covered from blood cultures: analysis of 524 episodes. J Clin 
Microbiol 2011; 49: 1598-1601 [PMID: 21325550 DOI: 10.1128/
JCM.01842-10]
21 Stevens DA, Kim KK, Johnson N, Lee JS, Hamilton JR. 
Halomonas johnsoniae: review of a medically underap-
preciated genus of growing human importance. Am J Med 
Sci 2013; 345: 335-338 [PMID: 22814360 DOI: 10.1097/
MAJ.0b013e31825600de]
22 Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Arta-
cho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, 
Neulinger SC, Däumer C, Heinsen FA, Latorre A, Barbas C, 
Seifert J, dos Santos VM, Ott SJ, Ferrer M, Moya A. Gut mi-
crobiota disturbance during antibiotic therapy: a multi-omic 
approach. Gut 2013; 62: 1591-1601 [PMID: 23236009 DOI: 
10.1136/gutjnl-2012-303184]
23 Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman 
DM, Smith S, Sikaroodi M, Gillevet PM. Linkage of gut mi-
crobiome with cognition in hepatic encephalopathy. Am J 
Physiol Gastrointest Liver Physiol 2012; 302: G168-G175 [PMID: 
21940902 DOI: 10.1152/ajpgi.00190.2011]
24 Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di 
Gregorio V, Lattanzi B, Riggio O. Muscle depletion increases 
the risk of overt and minimal hepatic encephalopathy: re-
sults of a prospective study. Metab Brain Dis 2013; 28: 281-284 
[PMID: 23224378 DOI: 10.1007/s11011-012-9365-z]
25 De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poul-
let JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact 
of diet in shaping gut microbiota revealed by a comparative 
study in children from Europe and rural Africa. Proc Natl 
Acad Sci USA 2010; 107: 14691-14696 [PMID: 20679230 DOI: 
10.1073/pnas.1005963107]
26 Quigley EM, Stanton C, Murphy EF. The gut microbiota 
and the liver. Pathophysiological and clinical implications. J 
Hepatol 2013; 58: 1020-1027 [PMID: 23183530 DOI: 10.1016/
j.jhep.2012.11.023]
27 Thalheimer U, Triantos CK, Samonakis DN, Patch D, Bur-
roughs AK. Infection, coagulation, and variceal bleeding 
in cirrhosis. Gut 2005; 54: 556-563 [PMID: 15753544 DOI: 
10.1136/gut.2004.048181]
28 Thalheimer U, De Iorio F, Capra F, del Mar Lleo M, Zu-
liani V, Ghidini V, Tafi MC, Caburlotto G, Gennari M, Bur-
roughs AK, Vantini I. Altered intestinal function precedes 
the appearance of bacterial DNA in serum and ascites in 
patients with cirrhosis: a pilot study. Eur J Gastroenterol 
Hepatol 2010; 22: 1228-1234 [PMID: 20512041 DOI: 10.1097/
MEG.0b013e32833b4b03]
29 Wiest R, Lawson M, Geuking M. Pathological bacterial 
translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209 
[PMID: 23993913 DOI: 10.1016/j.jhep.2013.07.044]
30 Bauer TM, Steinbrückner B, Brinkmann FE, Ditzen AK, 
Schwacha H, Aponte JJ, Pelz K, Kist M, Blum HE. Small 
intestinal bacterial overgrowth in patients with cirrhosis: 
prevalence and relation with spontaneous bacterial perito-
nitis. Am J Gastroenterol 2001; 96: 2962-2967 [PMID: 11693333 
DOI: 10.1111/j.1572-0241.2001.04668.x]
31 Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of 
autonomic neuropathy in chronic liver disease. Lancet 1992; 
339: 1462-1464 [PMID: 1351136 DOI: 10.1016/0140-6736(92)9
2042-E]
32 Maheshwari A, Thuluvath PJ. Autonomic neuropathy may 
be associated with delayed orocaecal transit time in patients 
with cirrhosis. Auton Neurosci 2005; 118: 135-139 [PMID: 
15795187 DOI: 10.1016/j.autneu.2005.02.003]
33 Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer 
U, Patch D, Burroughs AK. beta-Blockers protect against 
spontaneous bacterial peritonitis in cirrhotic patients: a 
meta-analysis. Liver Int 2009; 29: 1189-1193 [PMID: 19508620 
DOI: 10.1111/j.1478-3231.2009.02038.x]
34 Lo GH, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA, Yu 
HC, Hsu PI, Lai KH. Improved survival in patients receiv-
ing medical therapy as compared with banding ligation for 
the prevention of esophageal variceal rebleeding. Hepatology 
2008; 48: 580-587 [PMID: 18666235 DOI: 10.1002/hep.22358]
35 Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, 
Ceccarelli G, Riggio O, Venditti M. The chronic use of beta-
blockers and proton pump inhibitors may affect the rate of 
bacterial infections in cirrhosis. Liver Int 2014; Epub ahead of 
print [PMID: 24836902 DOI: 10.1111/liv.12593]
36 Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile 
acids and gut microbiota: unraveling a complex relationship. 
Gut Microbes 2013; 4: 382-387 [PMID: 23851335 DOI: 10.4161/
gmic.25723]
37 Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heu-
man DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, 
White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, 
Sikaroodi M, Bajaj JS. Modulation of the fecal bile acid pro-
file by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-955 
[PMID: 23333527 DOI: 10.1016/j.jhep.2013.01.003]
38 Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bam-
berg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut 
microbiota regulates bile acid metabolism by reducing the 
levels of tauro-beta-muricholic acid, a naturally occurring 
FXR antagonist. Cell Metab 2013; 17: 225-235 [PMID: 23395169 
DOI: 10.1016/j.cmet.2013.01.003]
39 Begley M, Gahan CG, Hill C. The interaction between bac-
teria and bile. FEMS Microbiol Rev 2005; 29: 625-651 [PMID: 
16102595 DOI: 10.1016/j.femsre.2004.09.003]
40 Quigley EM. New perspectives on the role of the intestinal 
flora in health and disease. J Gastrointestin Liver Dis 2006; 15: 
109-110 [PMID: 16802003]
41 Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cir-
rhosis. Hepatology 2005; 41: 422-433 [PMID: 15723320 DOI: 
10.1002/hep.20632]
42 Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, 
Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. 
Small intestinal bacterial overgrowth in human cirrhosis 
is associated with systemic endotoxemia. Am J Gastroen-
terol 2002; 97: 2364-2370 [PMID: 12358257 DOI: 10.1111/
j.1572-0241.2002.05791.x]
43 Quigley EM. Gastrointestinal dysfunction in liver disease 
and portal hypertension. Gut-liver interactions revisited. 
Dig Dis Sci 1996; 41: 557-561 [PMID: 8617136 DOI: 10.1007/
BF02282341]
44 Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. In-
testinal bacterial overgrowth and bacterial translocation in 
cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-1378 [PMID: 
9210626 DOI: 10.1016/S0168-8278(97)80474-6]
45 Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja 
A, Chawla Y. Role of small intestinal bacterial overgrowth 
and delayed gastrointestinal transit time in cirrhotic patients 
with minimal hepatic encephalopathy. J Hepatol 2010; 53: 
849-855 [PMID: 20675008 DOI: 10.1016/j.jhep.2010.05.017]
46 Morencos FC, de las Heras Castaño G, Martín Ramos L, 
López Arias MJ, Ledesma F, Pons Romero F. Small bowel 
bacterial overgrowth in patients with alcoholic cirrhosis. Dig 
Dis Sci 1995; 40: 1252-1256 [PMID: 7781442 DOI: 10.1007/
BF02065533]
47 Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, 
Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Ef-
fect of cisapride on intestinal bacterial overgrowth and bac-
terial translocation in cirrhosis. Hepatology 2000; 31: 858-863 
[PMID: 10733540 DOI: 10.1053/he.2000.5746]
Giannelli V et al . Dysbiosis and gut-liver axis in cirrhosis
16808 December 7, 2014|Volume 20|Issue 45|WJG|www.wjgnet.com
48 Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, 
Ditzen AK, Kist M, Blum HE. Diagnosis of small intestinal 
bacterial overgrowth in patients with cirrhosis of the liver: 
poor performance of the glucose breath hydrogen test. J 
Hepatol 2000; 33: 382-386 [PMID: 11019993 DOI: 10.1016/
S0168-8278(00)80273-1]
49 Pande C, Kumar A, Sarin SK. Small-intestinal bacterial over-
growth in cirrhosis is related to the severity of liver disease. 
Aliment Pharmacol Ther 2009; 29: 1273-1281 [PMID: 19302262 
DOI: 10.1111/j.1365-2036.2009.03994.x]
50 Simrén M, Stotzer PO. Use and abuse of hydrogen breath 
tests. Gut 2006; 55: 297-303 [PMID: 16474100 DOI: 10.1136/
gut.2005.075127]
51 Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal micro-
biota was assessed in cirrhotic patients with hepatitis B virus 
infection. Intestinal microbiota of HBV cirrhotic patients. 
Microb Ecol 2011; 61: 693-703 [PMID: 21286703 DOI: 10.1007/
s00248-010-9801-8]
52 Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P. Large-
scale survey of gut microbiota associated with MHE Via 16S 
rRNA-based pyrosequencing. Am J Gastroenterol 2013; 108: 
1601-1611 [PMID: 23877352 DOI: 10.1038/ajg.2013.221]
53 Xu M, Wang B, Fu Y, Chen Y, Yang F, Lu H, Chen Y, Xu J, 
Li L. Changes of fecal Bifidobacterium species in adult pa-
tients with hepatitis B virus-induced chronic liver disease. 
Microb Ecol 2012; 63: 304-313 [PMID: 21814872 DOI: 10.1007/
s00248-011-9925-5]
54 Wu ZW, Ling ZX, Lu HF, Zuo J, Sheng JF, Zheng SS, Li LJ. 
Changes of gut bacteria and immune parameters in liver 
transplant recipients. Hepatobiliary Pancreat Dis Int 2012; 11: 
40-50 [PMID: 22251469 DOI: 10.1016/S1499-3872(11)60124-0]
55 Zoetendal EG, von Wright A, Vilpponen-Salmela T, 
Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-
associated bacteria in the human gastrointestinal tract 
are uniformly distributed along the colon and differ from 
the community recovered from feces. Appl Environ Micro-
biol 2002; 68: 3401-3407 [PMID: 12089021 DOI: 10.1128/
AEM.68.7.3401-3407.2002]
56 Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, 
Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble 
NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet 
PM. Modulation of the metabiome by rifaximin in patients 
with cirrhosis and minimal hepatic encephalopathy. PLoS 
One 2013; 8: e60042 [PMID: 23565181 DOI: 10.1371/journal.
pone.0060042]
57 Berg RD, Garlington AW. Translocation of certain indig-
enous bacteria from the gastrointestinal tract to the mesen-
teric lymph nodes and other organs in a gnotobiotic mouse 
model. Infect Immun 1979; 23: 403-411 [PMID: 154474]
58 Benten D, Wiest R. Gut microbiome and intestinal barrier 
failure--the “Achilles heel” in hepatology? J Hepatol 2012; 56: 
1221-1223 [PMID: 22406521 DOI: 10.1016/j.jhep.2012.03.003]
59 Berg RD. Bacterial translocation from the gastrointestinal 
tract. Trends Microbiol 1995; 3: 149-154 [PMID: 7613757 DOI: 
10.1016/S0966-842X(00)88906-4]
60 Cuenca S, Sanchez E, Santiago A, El Khader I, Panda S, 
Vidal S, Camilo Nieto J, Juárez C, Sancho F, Guarner F, 
Soriano G, Guarner C, Manichanh C. Microbiome composi-
tion by pyrosequencing in mesenteric lymph nodes of rats 
with CCl4-induced cirrhosis. J Innate Immun 2014; 6: 263-271 
[PMID: 24296725 DOI: 10.1159/000356454]
61 Steffen EK, Berg RD, Deitch EA. Comparison of translo-
cation rates of various indigenous bacteria from the gas-
trointestinal tract to the mesenteric lymph node. J Infect 
Dis 1988; 157: 1032-1038 [PMID: 3283254 DOI: 10.1093/
infdis/157.5.1032]
62 Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, 
Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola 
A, Rodés J. Bacterial translocation of enteric organisms in 
patients with cirrhosis. J Hepatol 2001; 34: 32-37 [PMID: 
11211904 DOI: 10.1016/S0168-8278(00)00013-1]
63 Such J, Francés R, Muñoz C, Zapater P, Casellas JA, Cifuen-
tes A, Rodríguez-Valera F, Pascual S, Sola-Vera J, Carnicer 
F, Uceda F, Palazón JM, Pérez-Mateo M. Detection and 
identification of bacterial DNA in patients with cirrhosis and 
culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 
135-141 [PMID: 12085357 DOI: 10.1053/jhep.2002.33715]
64 Llovet JM, Bartolí R, March F, Planas R, Viñado B, Cabré E, 
Arnal J, Coll P, Ausina V, Gassull MA. Translocated intes-
tinal bacteria cause spontaneous bacterial peritonitis in cir-
rhotic rats: molecular epidemiologic evidence. J Hepatol 1998; 
28: 307-313 [PMID: 9580278 DOI: 10.1016/0168-8278(88)8001
8-7]
65 Pérez-Paramo M, Muñoz J, Albillos A, Freile I, Portero F, 
Santos M, Ortiz-Berrocal J. Effect of propranolol on the fac-
tors promoting bacterial translocation in cirrhotic rats with 
ascites. Hepatology 2000; 31: 43-48 [PMID: 10613726 DOI: 
10.1002/hep.510310109]
66 Bellot P, Francés R, Such J. Pathological bacterial transloca-
tion in cirrhosis: pathophysiology, diagnosis and clinical 
implications. Liver Int 2013; 33: 31-39 [PMID: 23121656 DOI: 
10.1111/liv.12021]
67 Francés R, González-Navajas JM, Zapater P, Muñoz C, Caño 
R, Pascual S, Santana F, Márquez D, Pérez-Mateo M, Such J. 
Translocation of bacterial DNA from Gram-positive micro-
organisms is associated with a species-specific inflammatory 
response in serum and ascitic fluid of patients with cirrhosis. 
Clin Exp Immunol 2007; 150: 230-237 [PMID: 17822441 DOI: 
10.1111/j.1365-2249.2007.03494.x]
68 Albillos A, de la Hera A, González M, Moya JL, Calleja JL, 
Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased 
lipopolysaccharide binding protein in cirrhotic patients 
with marked immune and hemodynamic derangement. 
Hepatology 2003; 37: 208-217 [PMID: 12500206 DOI: 10.1053/
jhep.2003.50038]
69 Steffen EK, Berg RD. Relationship between cecal population 
levels of indigenous bacteria and translocation to the mesen-
teric lymph nodes. Infect Immun 1983; 39: 1252-1259 [PMID: 
6341234]
70 Sánchez E, Casafont F, Guerra A, de Benito I, Pons-Romero F. 
Role of intestinal bacterial overgrowth and intestinal motility 
in bacterial translocation in experimental cirrhosis. Rev Esp 
Enferm Dig 2005; 97: 805-814 [PMID: 16438624 DOI: 10.4321/
S1130-01082005001100005]
71 Cariello R, Federico A, Sapone A, Tuccillo C, Scialdone VR, 
Tiso A, Miranda A, Portincasa P, Carbonara V, Palasciano G, 
Martorelli L, Esposito P, Cartenì M, Del Vecchio Blanco C, 
Loguercio C. Intestinal permeability in patients with chronic 
liver diseases: Its relationship with the aetiology and the 
entity of liver damage. Dig Liver Dis 2010; 42: 200-204 [PMID: 
19502117 DOI: 10.1016/j.dld.2009.05.001]
72 Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti 
G, Merra G, Dal Lago A, Ojetti V, Ainora ME, Santoro M, 
Ghirlanda G, Gasbarrini A. Intestinal permeability in cirrhot-
ic patients with and without spontaneous bacterial perito-
nitis: is the ring closed? Am J Gastroenterol 2010; 105: 323-327 
[PMID: 19844200 DOI: 10.1038/ajg.2009.558]
73 Kalaitzakis E, Johansson JE, Bjarnason I, Björnsson E. Intes-
tinal permeability in cirrhotic patients with and without as-
cites. Scand J Gastroenterol 2006; 41: 326-330 [PMID: 16497621 
DOI: 10.1080/00365520510024278]
74 Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune 
dysfunction in cirrhosis. World J Gastroenterol 2014; 20: 
2564-2577 [PMID: 24627592 DOI: 10.3748/wjg.v20.i10.2564]
75 Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante 
G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A. The role of 
intestinal microbiota and the immune system. Eur Rev Med 
Pharmacol Sci 2013; 17: 323-333 [PMID: 23426535]
Giannelli V et al . Dysbiosis and gut-liver axis in cirrhosis
16809 December 7, 2014|Volume 20|Issue 45|WJG|www.wjgnet.com
76 Teltschik Z, Wiest R, Beisner J, Nuding S, Hofmann C, 
Schoelmerich J, Bevins CL, Stange EF, Wehkamp J. Intesti-
nal bacterial translocation in rats with cirrhosis is related to 
compromised Paneth cell antimicrobial host defense. Hepa-
tology 2012; 55: 1154-1163 [PMID: 22095436 DOI: 10.1002/
hep.24789]
77 Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba 
J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, 
Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka 
J, Bernardi M, Arroyo V. Acute-on-chronic liver failure is 
a distinct syndrome that develops in patients with acute 
decompensation of cirrhosis. Gastroenterology 2013; 144: 
1426-1437, 1437.e1-9 [PMID: 23474284 DOI: 10.1053/
j.gastro.2013.02.042]
78 Campillo B, Richardet JP, Kheo T, Dupeyron C. Nosocomial 
spontaneous bacterial peritonitis and bacteremia in cirrhotic 
patients: impact of isolate type on prognosis and characteris-
tics of infection. Clin Infect Dis 2002; 35: 1-10 [PMID: 12060868 
DOI: 10.1086/340617]
79 Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone 
M, Ridola L, Attili AF, Venditti M. Cirrhotic patients are 
at risk for health care-associated bacterial infections. Clin 
Gastroenterol Hepatol 2010; 8: 979-985 [PMID: 20621200 DOI: 
10.1016/j.cgh.2010.06.024]
80 Giannelli V, Di Gregorio V, Lucidi C, Iebba V, Santangelo 
F, Attili AF, Riggio O, Schippa S, Merli M. Does the gut mi-
crobiota modulate the inflammatory state in cirrhotic host? J 
Hepatol 2014; 60: S41
81 Schnabl B, Brenner DA. Interactions between the intestinal 
microbiome and liver diseases. Gastroenterology 2014; 146: 
1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
82 Assimakopoulos SF, Scopa CD, Vagianos CE. Pathophysi-
ology of increased intestinal permeability in obstructive 
jaundice. World J Gastroenterol 2007; 13: 6458-6464 [PMID: 
18161914 DOI: 10.3748/wjg.13.6458]
83 Runyon BA, Squier S, Borzio M. Translocation of gut bacte-
ria in rats with cirrhosis to mesenteric lymph nodes partially 
explains the pathogenesis of spontaneous bacterial peritoni-
tis. J Hepatol 1994; 21: 792-796 [PMID: 7890896 DOI: 10.1016/
S0168-8278(94)80241-6]
84 Yeh DC, Wu CC, Ho WM, Cheng SB, Lu IY, Liu TJ, P’eng FK. 
Bacterial translocation after cirrhotic liver resection: a clini-
cal investigation of 181 patients. J Surg Res 2003; 111: 209-214 
[PMID: 12850464 DOI: 10.1016/S0022-4804(03)00112-4]
85 Steib CJ, Hartmann AC, v Hesler C, Benesic A, Hennen-
berg M, Bilzer M, Gerbes AL. Intraperitoneal LPS amplifies 
portal hypertension in rat liver fibrosis. Lab Invest 2010; 90: 
1024-1032 [PMID: 20212458 DOI: 10.1038/labinvest.2010.60]
86 Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting 
J. The effect of selective intestinal decontamination on the 
hyperdynamic circulatory state in cirrhosis. A randomized 
trial. Ann Intern Med 2003; 139: 186-193 [PMID: 12899586 
DOI: 10.7326/0003-4819-139-3-200308050-00008]
87 Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang 
ZD, DuPont HL, Shah VH. Intestinal decontamination inhib-
its TLR4 dependent fibronectin-mediated cross-talk between 
stellate cells and endothelial cells in liver fibrosis in mice. 
J Hepatol 2012; 56: 893-899 [PMID: 22173161 DOI: 10.1016/
j.jhep.2011.11.013]
88 Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic 
inflammation and ammonia in hepatic encephalopathy. 
Metab Brain Dis 2013; 28: 1-5 [PMID: 23224356 DOI: 10.1007/
s11011-012-9370-2]
89 Sharma P, Sharma BC. Rifaximin treatment in hepatic en-
cephalopathy. N Engl J Med 2010; 362: 2423-2424; author reply 
2424-2425 [PMID: 20578274 DOI: 10.1056/NEJMc1004719]
90 Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 
2009; 27: 147-163 [PMID: 19302037 DOI: 10.1146/annurev.
immunol.021908.132629]
91 Chen GY, Nuñez G. Sterile inflammation: sensing and react-
ing to damage. Nat Rev Immunol 2010; 10: 826-837 [PMID: 
21088683 DOI: 10.1038/nri2873]
92 Takeuchi O, Akira S. Pattern recognition receptors and in-
flammation. Cell 2010; 140: 805-820 [PMID: 20303872 DOI: 
10.1016/j.cell.2010.01.022]
93 Yamamoto M, Takeda K. Current views of toll-like receptor 
signaling pathways. Gastroenterol Res Pract 2010; 2010: 240365 
[PMID: 21197425 DOI: 10.1155/2010/240365]
94 Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej 
N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky 
JJ, Layden TJ, Wright TL, White T, Cheung RC. A 7 gene sig-
nature identifies the risk of developing cirrhosis in patients 
with chronic hepatitis C. Hepatology 2007; 46: 297-306 [PMID: 
17461418 DOI: 10.1002/hep.21695]
95 Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry 
AW, McKim SE, Parsons C, Rippe RA, Wheeler MD. LPS sig-
naling enhances hepatic fibrogenesis caused by experimental 
cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 
2006; 290: G1318-G1328 [PMID: 16439470 DOI: 10.1152/ajp-
gi.00405.2005]
96 Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, 
Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signal-
ing and hepatic fibrosis. Nat Med 2007; 13: 1324-1332 [PMID: 
17952090 DOI: 10.1038/nm1663]
97 Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. 
Toll-like receptor 4 is involved in the mechanism of early 
alcohol-induced liver injury in mice. Hepatology 2001; 34: 
101-108 [PMID: 11431739 DOI: 10.1053/jhep.2001.25350]
98 Yin M, Gäbele E, Wheeler MD, Connor H, Bradford BU, Di-
kalova A, Rusyn I, Mason R, Thurman RG. Alcohol-induced 
free radicals in mice: direct toxicants or signaling molecules? 
Hepatology 2001; 34: 935-942 [PMID: 11679964 DOI: 10.1053/
jhep.2001.28888]
99 Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. 
Antibiotics prevent liver injury in rats following long-term 
exposure to ethanol. Gastroenterology 1995; 108: 218-224 
[PMID: 7806045 DOI: 10.1016/0016-5085(95)90027-6]
100 Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy 
CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman 
L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, 
Forbes WP. Rifaximin treatment in hepatic encephalopathy. 
N Engl J Med 2010; 362: 1071-1081 [PMID: 20335583 DOI: 
10.1056/NEJMoa0907893]
101 Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaser-
ouni S, McClain CJ, Bischoff SC. Antibiotics protect against 
fructose-induced hepatic lipid accumulation in mice: role of 
endotoxin. J Hepatol 2008; 48: 983-992 [PMID: 18395289 DOI: 
10.1016/j.jhep.2008.01.035]
102 Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic 
encephalopathy. Metab Brain Dis 2013; 28: 307-312 [PMID: 
23389621 DOI: 10.1007/s11011-013-9383-5]
103 Dhiman RK. Gut microbiota and hepatic encephalopathy. 
Metab Brain Dis 2013; 28: 321-326 [PMID: 23463489 DOI: 
10.1007/s11011-013-9388-0]
104 Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr 
JM, Jonas S, Bengmark S, Neuhaus P. Supply of pre- and 
probiotics reduces bacterial infection rates after liver 
transplantation--a randomized, double-blind trial. Am J 
Transplant 2005; 5: 125-130 [PMID: 15636620 DOI: 10.1111/
j.1600-6143.2004.00649.x]
105 Lata J, Novotný I, Príbramská V, Juránková J, Fric P, Kroupa 
R, Stibůrek O. The effect of probiotics on gut flora, level of 
endotoxin and Child-Pugh score in cirrhotic patients: results 
of a double-blind randomized study. Eur J Gastroenterol 
Hepatol 2007; 19: 1111-1113 [PMID: 17998837 DOI: 10.1097/
MEG.0b013e3282efa40e]
106 Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. 
Effects of the adjunctive probiotic VSL#3 on portal haemo-
Giannelli V et al . Dysbiosis and gut-liver axis in cirrhosis
16810 December 7, 2014|Volume 20|Issue 45|WJG|www.wjgnet.com
dynamics in patients with cirrhosis and large varices: a ran-
domized trial. Liver Int 2013; 33: 1148-1157 [PMID: 23601333 
DOI: 10.1111/liv.12172]
107 Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma 
RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion 
DG. Probiotic yogurt for the treatment of minimal hepatic 
encephalopathy. Am J Gastroenterol 2008; 103: 1707-1715 
[PMID: 18691193 DOI: 10.1111/j.1572-0241.2008.01861.x]
P- Reviewer: Bujanda L, Hahm KB, Ohkohchi N 
S- Editor: Ma YJ    L- Editor: A    E- Editor: Wang CH 
Giannelli V et al . Dysbiosis and gut-liver axis in cirrhosis
                                      © 2014 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4   5
